In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

(CercleFinance.com) - Moderna a publié sur son site internet une lettre aux actionnaires rédigée par son directeur général, Stéphane Bancel ...

Here are the five things you need to know, including the national day of mourning for Jimmy Carter, California wildfires, Newbury Street rents, and quality goat time ...

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...

Pour 2025, les priorités de Moderna incluent la maximisation de la disponibilité et de la part de marché de ses vaccins ...

Moderna CEO Stéphane Bancel drew on the experience of the pandemic, when misinformation about his Spikevax vaccine and other products was rife, to argue “our job is really to get the facts out, ...

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through ...

In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year ...

In fact, in a promotional video published in parallel with this recent announcement, Bancel hinted that Moderna has ambitious plans to launch multiple products in the coming years, stating that ...